WJ

Waseem Javeed

Director Director DIN 05187303
DIN 05187303 First appointment Feb 2012 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since Feb 2012
Shareholding value β€’β€’β€’β€’ Premium profile

About Waseem Javeed

Data last updated:

Waseem Javeed was a Director at Module Pharmaceutical Private Limited (2012–2013) and Director at Medjons Pharmaceuticals Private Limited (from 2014). The companies operate in Pharma.

DIN 05187303
Primary Designation Director
Industry Pharma
First Appointment 24 Feb 2012
Oldest Company Age 11 yrs

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director24 Feb 20122012₹87.1 Lakh (FY 2025)Active
Director09 Dec 20142014Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Medjons Pharmaceuticals Private Limited
Module Pharmaceutical Private Limited
Premium access

Shareholding and investment profile for Waseem Javeed

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Waseem Javeed

Waseem Javeed was first appointed on 24 Feb 2012 as Director at Module Pharmaceutical Private Limited. The most recent appointment on record is 09 Dec 2014 at Medjons Pharmaceuticals Private Limited.

Waseem Javeed held 2 earlier board appointments: Module Pharmaceutical Private Limited (Director, 24 Feb 2012 to 02 Feb 2013); Medjons Pharmaceuticals Private Limited (Director, from 09 Dec 2014).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available